Widening loss due to higher revenue in the Americas business and increased fixed costs
First written in FY2018-Q1. 21 of 36 entries say "Worsened", first in FY2018-Q2. Latest entry: 2026-08-07.
Advanex moved to the "Worse" side of this theme in 2017, 5 years before the typical company in this theme (2022).
The whole theme swung hardest in 2017: 2 of 9 companies on the "Worse" side.
1 other company's latest entry also says "Worsened".
- FY2026AdvancedAnnual report
「As demand from the medical sector continued to expand and improvements at the Mexico plant progressed, net sales increased 11.2% year on year to ¥6,014 million and segment income increased 43.4% to ¥276 million.」
The Americas reported higher revenue and profit as the medical business expanded and the Mexico plant improved, with segment profit increasing 43.4%. - FY2026-H1AdvancedAnnual report
「Progress at the Mexico Plant and continued expansion in the medical sector drove sales up 18.3% year on year to ¥3,016 million. The segment posted a profit of ¥327 million, compared with a loss of ¥23 million in the same period of the previous year.」
The Americas business reported higher revenue and moved from a loss of ¥23 million in the same period of the previous year to a profit of ¥327 million as the Mexico plant improved and the medical business expanded. - FY2025AchievedAnnual report
「As production for the medical sector increased substantially at the U.S. plant, net sales rose 27.9% from the previous fiscal year to ¥5,410 million. The segment posted a profit of ¥192 million, compared with a loss of ¥455 million in the previous fiscal year, and returned to profitability partly due to higher profit at the U.S. plant.」
The Americas business returned to profitability as increased production for the medical sector drove higher revenue, with the segment moving from a loss of ¥455 million in the previous fiscal year to a profit of ¥192 million. - FY2025-H1AdvancedAnnual report
「As production for the medical sector increased substantially at the U.S. plant, net sales rose 18.0% year on year to ¥2,550 million. The segment loss narrowed substantially to ¥23 million, compared with a loss of ¥163 million in the same period of the previous year, partly due to higher profit at the U.S. plant.」
The Americas reported higher revenue due to increased medical production at the U.S. plant, while the segment loss narrowed from ¥163 million in the same period of the previous year to ¥23 million. - FY2024AdvancedAnnual report
「As production for the automotive and medical sectors ramped up at the U.S. and Mexico plants, net sales rose 45.7% from the previous fiscal year to ¥4,231 million. Although higher costs, including fixed costs, resulting from the stronger Mexican peso weighed on the segment, the loss narrowed to ¥455 million, compared with a loss of ¥1,041 million in the previous fiscal year, as profitability at the U.S. plant improved.」
The Americas reported a substantial increase in revenue, while improved profitability at the U.S. plant narrowed the full-year segment loss from ¥1,041 million to ¥455 million. - FY2024-Q3AdvancedAnnual report
「Progress in ramping up automotive and medical production at the US and Mexico plants drove sales up 52.5% year on year to ¥3,182 million. Although the stronger Mexican peso increased fixed costs and other expenses, improved profitability at the US plant narrowed the segment loss to ¥328 million from ¥746 million in the same quarter of the previous year.」
The Americas reported higher revenue as production for the automotive and medical sectors ramped up, while improved profitability at the U.S. plant narrowed the loss from ¥746 million in the same period of the previous year to ¥328 million. - FY2024-Q2AdvancedAnnual report
「Progress in ramping up automotive and medical production at the US and Mexico plants drove sales up 58.0% year on year to ¥2,162 million. Although the stronger Mexican peso increased fixed costs and other expenses, improved profitability at the US plant narrowed the segment loss to ¥163 million from ¥546 million in the same quarter of the previous year.」
The Americas reported higher revenue as production for the automotive and medical sectors ramped up, while improved profitability at the U.S. plant narrowed the loss from the same period of the previous year. - FY2024-Q1AdvancedAnnual report
「Progress in ramping up automotive and medical production at the US and Mexico plants drove sales up 53.7% year on year to ¥1,007 million. Although the stronger Mexican peso increased fixed costs and other expenses, profitability improved at both plants, narrowing the segment loss to ¥84 million from ¥283 million in the same quarter of the previous year.」
The Americas reported a substantial increase in revenue as production ramped up at the U.S. and Mexico plants and profitability improved, while the segment loss also narrowed from the same period of the previous year. - FY2023WorsenedAnnual report
「Despite delays in starting operations at the new Tennessee plant, net sales rose 14.5% from the previous fiscal year to ¥2,904 million, partly due to the weaker yen. The segment loss was ¥1,041 million, compared with a loss of ¥611 million in the previous fiscal year, due in part to the delays at the new Tennessee plant and higher material costs.」
The Americas reported higher revenue due to the weaker yen, while the segment loss widened from ¥611 million to ¥1,041 million due to delays in starting operations at the new Tennessee plant and higher material costs. - FY2023-Q3WorsenedAnnual report
「Despite delays in starting operations at the new Tennessee plant, net sales rose 4.3% year on year to ¥2,087 million, partly due to the weaker yen. The segment loss was ¥746 million, compared with a loss of ¥467 million in the same quarter of the previous year, due in part to the delays at the new Tennessee plant and higher material costs.」
The Americas reported higher revenue, but the segment loss widened from ¥467 million in the same period of the previous year to ¥746 million due to delays in starting operations at the new Tennessee plant and higher material costs. - FY2023-Q2WorsenedAnnual report
「Although operations at the new Tennessee Plant were delayed, progress in ramping up production at the Mexico Plant and the weaker yen drove sales up slightly year on year to ¥1,368 million. The segment loss was ¥546 million, compared with a loss of ¥340 million in the same quarter of the previous year, due in part to the delay at the new Tennessee Plant and higher material costs.」
Sales in the Americas increased only marginally, while the segment loss widened from ¥340 million in the same period of the previous year to ¥546 million due to delays in starting operations at the new Tennessee plant and higher material costs. - FY2023-Q1WorsenedAnnual report
「Although operations at the new Tennessee Plant were delayed, progress in ramping up production at the Mexico Plant drove sales up 9.7% year on year to ¥655 million. The segment loss was ¥283 million, compared with a loss of ¥222 million in the same quarter of the previous year, due in part to the delay at the new Tennessee Plant and higher raw material costs.」
The Americas reported higher revenue as production ramped up at the Mexico plant, while the segment loss widened due to delays in starting operations at the new Tennessee plant and higher raw-material costs. - FY2022WorsenedAnnual report
「(Americas) Demand for automotive and medical applications recovered, and sales increased 15.9% from the previous fiscal year to ¥2,536 million. However, the segment loss was ¥611 million (a loss of ¥527 million in the previous fiscal year) due to costs incurred to launch a project at the Mexico plant and other factors.」
The Americas reported higher revenue due to recovering demand, while the segment loss widened from ¥527 million to ¥611 million due to Mexico plant project start-up costs and other factors. - FY2022-Q3WorsenedAnnual report
「The recovery in automotive and medical demand drove sales up 29.4% year on year to ¥2,002 million, but the segment loss was ¥467 million, compared with a loss of ¥262 million in the same quarter of the previous year, due to expenses associated with relocating the US plant and project start-up costs at the Mexico Plant.」
The Americas reported higher revenue due to recovering demand, while the segment loss widened from ¥262 million in the same period of the previous year to ¥467 million due to US plant relocation costs and Mexico plant project start-up costs. - FY2022-Q2WorsenedAnnual report
「The recovery in automotive and medical demand drove sales up 48.5% year on year to ¥1,362 million, but the segment loss was ¥340 million, compared with a loss of ¥163 million in the same quarter of the previous year, due to expenses associated with relocating the US plant and project start-up costs at the Mexico Plant.」
The Americas reported higher revenue due to recovering demand, while the segment loss widened from ¥163 million in the same period of the previous year to ¥340 million due to US plant relocation costs and Mexico plant project start-up costs. - FY2022-Q1WorsenedAnnual report
「The recovery in automotive and medical demand drove sales up 76.7% year on year to ¥597 million, but the segment loss was ¥222 million, compared with a loss of ¥151 million in the same quarter of the previous year, due to expenses associated with relocating the US plant and project start-up costs at the Mexico Plant.」
The Americas reported higher revenue due to recovering demand, while the segment loss widened from ¥151 million in the same period of the previous year to ¥222 million due to US plant relocation costs and Mexico plant start-up costs. - FY2021WorsenedAnnual report
「In addition to lower demand, particularly for automotive applications, the Mexico plant was closed for a period at the direction of the Mexican government. Sales therefore decreased 14.6% from the previous fiscal year to ¥2,188 million, and the segment loss was ¥527 million (a loss of ¥360 million in the previous fiscal year).」
The Americas business reported lower revenue due to lower automotive demand and the period of closure of the Mexico plant, while the segment loss widened from ¥360 million in the previous fiscal year to ¥527 million. - FY2021-Q3WorsenedAnnual report
「In addition to a particularly sharp decline in automotive demand, the Mexico Plant was closed for approximately 2 months at the direction of the Mexican government. As a result, sales fell 17.7% year on year to ¥1,547 million, and the segment loss was ¥262 million, compared with a loss of ¥220 million in the same quarter of the previous year.」
The Americas business reported lower revenue due to lower automotive demand and the approximately 2-month closure of the Mexico plant, while the segment loss widened from the previous period. - FY2021-Q2WorsenedAnnual report
「In addition to lower demand, particularly for automotive applications, the Mexico plant was closed for approximately 2 months at the direction of the Mexican government. Sales therefore decreased 22.2% year on year to ¥917 million, and the segment loss was ¥163 million (a loss of ¥132 million in the same quarter of the previous year).」
The Americas business reported lower revenue due to lower automotive demand and the approximately 2-month closure of the Mexico plant, while the segment loss widened from ¥132 million in the same period of the previous year to ¥163 million. - FY2021-Q1WorsenedAnnual report
「In addition to a particularly sharp decline in automotive demand, the Mexico Plant was closed for approximately 2 months at the direction of the Mexican government. As a result, sales fell 50.2% year on year to ¥338 million, and the segment loss was ¥151 million, compared with a loss of ¥88 million in the same quarter of the previous year.」
The Americas business reported a 50.2% decline in sales and a wider segment loss year on year due to lower automotive demand and the approximately 2-month closure of the Mexico plant. - FY2020Higher revenue, but loss remained flatAnnual report
「Sales increased 4.4% from the previous fiscal year to ¥2,563 million, as medical applications expanded steadily despite a decline in sales to the housing equipment and infrastructure markets. The segment loss was ¥360 million (a loss of ¥360 million in the previous fiscal year) due to higher maintenance costs and other expenses at the Mexican subsidiary.」
The Americas reported higher revenue due to growth in medical applications, but the segment loss remained at the same level as in the previous fiscal year due to maintenance costs and other expenses at the Mexican subsidiary. - FY2020-Q3MitigatedAnnual report
「Although sales to the housing equipment and infrastructure sectors declined, expansion in the medical sector and other factors drove sales up 3.3% year on year to ¥1,880 million. The segment loss was ¥220 million, compared with a loss of ¥264 million in the same quarter of the previous year, as the deficit narrowed following the partial start-up of the Mexico Plant's automotive production line.」
The Americas reported higher revenue, and the segment loss narrowed from ¥264 million in the same period of the previous year to ¥220 million as part of the Mexico plant's automotive production lines began operating. - FY2020-Q2MitigatedAnnual report
「Sales fell 2.2% year on year to ¥1,179 million due to sluggish automotive demand and the impact of foreign exchange. The segment loss was ¥132 million, compared with a loss of ¥205 million in the same quarter of the previous year, as the deficit narrowed following the partial start-up of the Mexico Plant's automotive production line.」
The Americas reported lower revenue, while the segment loss narrowed from ¥205 million in the same period of the previous year to ¥132 million as part of the Mexico plant's automotive production lines began operating. - FY2020-Q1WorsenedAnnual report
「Some production lines at the Mexico plant entered full-scale operation, and sales increased 10.5% year on year to ¥678 million as medical applications performed well. The segment loss was ¥88 million (a loss of ¥65 million in the same quarter of the previous year), partly due to higher Mexico plant start-up costs.」
The Americas reported higher revenue, while the segment loss widened from ¥65 million in the same period of the previous year to ¥88 million due to higher Mexico plant start-up costs. - FY2019-Q3WorsenedAnnual report
「Strong performance in the medical sector and other factors drove sales up 10.7% year on year to ¥1,821 million, but the segment loss was ¥264 million, compared with a loss of ¥261 million in the same quarter of the previous year, due in part to higher Mexico Plant start-up costs and sharply higher material costs.」
The Americas reported higher revenue, while the segment loss widened year on year due to higher Mexico plant start-up costs and material costs. - FY2019-Q2WorsenedAnnual report
「Strong performance in the medical sector and other factors drove sales up 6.4% year on year to ¥1,206 million, but the segment loss was ¥205 million, compared with a loss of ¥128 million in the same quarter of the previous year, due in part to higher Mexico Plant start-up costs and sharply higher material costs.」
The Americas reported higher revenue, while the segment loss widened from ¥128 million in the same period of the previous year to ¥205 million due to higher Mexico plant start-up costs and higher material costs. - FY2019-Q1WorsenedAnnual report
「Sales increased 7.0% year on year to ¥613 million as medical applications performed well, but fixed costs increased due to capital investment and additional hiring in preparation for expanded production. The segment loss was ¥65 million (a loss of ¥40 million in the same quarter of the previous year).」
The Americas reported higher revenue, while the segment loss widened from ¥40 million in the same period of the previous year to ¥65 million due to higher fixed costs from capital investment and additional hiring in preparation for expanded production. - FY2018WorsenedAnnual report
「Sales increased 10.4% from the previous fiscal year to ¥2,193 million as automotive applications performed well, but the segment loss was ¥369 million (a loss of ¥161 million in the previous fiscal year) due to higher fixed costs associated with upfront investment at the Mexico plant, among other factors.」
The Americas reported higher revenue due to strong automotive applications, while the segment loss widened due to higher fixed costs associated with upfront investment at the Mexico plant, among other factors. - FY2018-Q3WorsenedAnnual report
「Sales increased 16.3% year on year to ¥1,645 million as automotive applications performed well, but the segment loss was ¥261 million (a loss of ¥96 million in the same quarter of the previous year) due to higher fixed costs associated with upfront investment at the Mexico plant, among other factors.」
The Americas reported higher revenue due to strong automotive applications, while the segment loss widened from ¥96 million in the same period of the previous year to ¥261 million due to higher fixed costs associated with upfront investment at the Mexico plant, among other factors. - FY2018-Q2WorsenedAnnual report
「Sales increased 22.6% year on year to ¥1,134 million as automotive applications performed well, but the segment loss was ¥128 million (a loss of ¥53 million in the same quarter of the previous year) due to higher fixed costs at the second Mexico plant and second US plant, among other factors.」
The Americas reported higher revenue due to strong automotive applications, while the segment loss widened from ¥53 million in the same period of the previous year to ¥128 million due to higher fixed costs at both second plants, among other factors. - FY2018-Q1First statedAnnual report
「Sales increased 24.2% year on year to ¥573 million as automotive applications performed well, but the segment loss was ¥40 million (a loss of ¥23 million in the same quarter of the previous year) due to higher fixed costs at the second Mexico plant and second US plant, among other factors.」
The Americas reported higher revenue due to strong automotive applications, while the segment loss widened due to higher fixed costs at the second Mexico plant and second US plant, among other factors.